Biogen Asks FDA To Approve Alzheimer's Drug — Why It's Far From A Slam Dunk

Biogen Asks FDA To Approve Alzheimer's Drug — Why It's Far From A Slam Dunk

Biogen stock popped Wednesday after the biotech giant asked the Food and Drug Administration to approve its controversial Alzheimer's treatment, aducanumab.